Literature DB >> 1323620

Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from rmp deletion mutants.

L M Wetzler1, M S Blake, K Barry, E C Gotschlich.   

Abstract

The gonococcal major outer membrane protein, Por (protein I), is a potential vaccine candidate. A large-scale animal trial compared the immunogenicity of Por inserted in liposomes (mimicking its in vivo structure) with previously used vaccines containing Por. Por was purified from Rmp (protein III)-negative gonococcal mutants and made into five different formulations: proteosomes, proteosomes absorbed to alum, liposomes, gonococcal membrane blebs, and gonococcal membrane blebs absorbed to alum. Por liposomes induced the greatest amount of Por antibodies; proteosomes and both preparations of blebs induced minimal amounts of Por antibodies. Proteosomes absorbed to alum induced slightly lower amounts of Por antibodies than did liposomes, especially when protein IA was used. Whole-organism absorption studies revealed that a significantly greater percentage of liposome-induced Por antibodies recognized exposed portions of the protein than did proteosome- or proteosome/alum-induced antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323620     DOI: 10.1093/infdis/166.3.551

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Gonococcal genes encoding transferrin-binding proteins A and B are arranged in a bicistronic operon but are subject to differential expression.

Authors:  C Ronpirin; A E Jerse; C N Cornelissen
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.

Authors:  N Bhasin; Y Ho; L M Wetzler
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations.

Authors:  Melanie Olesky; Shuqing Zhao; Robert L Rosenberg; Robert A Nicholas
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

5.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 6.  Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Authors:  Lee M Wetzler
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

7.  Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.

Authors:  R Bjerknes; H K Guttormsen; C O Solberg; L M Wetzler
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Th1 and Th2 cell involvement in immune response to Salmonella typhimurium porins.

Authors:  M Galdiero; L De Martino; A Marcatili; I Nuzzo; M Vitiello; G Cipollaro de l'Ero
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

9.  Role of protein tyrosine kinase and Erk1/2 activities in the Toll-like receptor 2-induced cellular activation of murine B cells by neisserial porin.

Authors:  Heather MacLeod; Navneet Bhasin; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

10.  Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.

Authors:  H K Guttormsen; L M Wetzler; A Naess
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.